PL194025B1
(pl)
|
1996-10-18 |
2007-04-30 |
Vertex Pharma |
Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych
|
CN102372764A
(zh)
|
2000-07-21 |
2012-03-14 |
先灵公司 |
用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽
|
SV2003000617A
(es)
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
JP2003007697A
(ja)
*
|
2001-06-21 |
2003-01-10 |
Hitachi Kokusai Electric Inc |
半導体装置の製造方法、基板処理方法および基板処理装置
|
MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
CN100591662C
(zh)
|
2003-06-17 |
2010-02-24 |
先灵公司 |
制备3-(氨基)-3-环丁基甲基-2-羟基-丙酰胺或其盐的方法和中间体
|
CN101823965B
(zh)
*
|
2003-06-17 |
2012-12-19 |
默沙东公司 |
制备(1r,2s,5s)-6,6-二甲基-3-氮杂双环[3,1,0]己烷-2-羧酸酯或其盐的方法和中间体
|
AR044694A1
(es)
*
|
2003-06-17 |
2005-09-21 |
Schering Corp |
Proceso y compuestos intermedios para la preparacion de (1r, 2s,5s) - 3 azabiciclo [3,1,0] hexano-2- carboxamida, n- [3- amino-1- (ciclobutilmetil) - 2, 3 - dioxopropil] -3- [ (2s) - 2 - [[ [ 1,1- dimetiletil] amino] carbonilamino] -3,3-dimetil -1- oxobutil]-6,6 dimetilo
|
US7449447B2
(en)
*
|
2003-08-26 |
2008-11-11 |
Schering Corporation |
Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus
|
MY148123A
(en)
|
2003-09-05 |
2013-02-28 |
Vertex Pharma |
Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
|
US7592419B2
(en)
*
|
2003-09-26 |
2009-09-22 |
Schering Corporation |
Macrocyclic inhibitors of hepatitis C virus NS3-serine protease
|
US20110150835A1
(en)
*
|
2003-09-26 |
2011-06-23 |
Schering Corporation |
Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease
|
US7491794B2
(en)
*
|
2003-10-14 |
2009-02-17 |
Intermune, Inc. |
Macrocyclic compounds as inhibitors of viral replication
|
CN100509784C
(zh)
*
|
2003-12-11 |
2009-07-08 |
先灵公司 |
丙型肝炎病毒ns3/ns4a丝氨酸蛋白酶的抑制剂
|
CA2552319C
(en)
|
2004-01-30 |
2012-08-21 |
Medivir Ab |
Hcv ns-3 serine protease inhibitors
|
EP1711515A2
(en)
|
2004-02-04 |
2006-10-18 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
|
EP2626354A1
(en)
|
2004-02-20 |
2013-08-14 |
Boehringer Ingelheim International GmbH |
Viral polymerase inhibitors
|
WO2005085242A1
(en)
*
|
2004-02-27 |
2005-09-15 |
Schering Corporation |
Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus
|
ATE438622T1
(de)
|
2004-02-27 |
2009-08-15 |
Schering Corp |
3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
|
DE602005023224D1
(de)
*
|
2004-02-27 |
2010-10-07 |
Schering Corp |
Neuartige Verbindungen als Hemmer von Hepatitis C-Virus NS3-Serinprotease
|
JP2007525521A
(ja)
*
|
2004-02-27 |
2007-09-06 |
シェーリング コーポレイション |
C型肝炎ウイルスns3セリンプロテアーゼのインヒビターとしてのシクロブテンジオン基含有化合物
|
CA2557322A1
(en)
*
|
2004-02-27 |
2005-09-15 |
Schering Corporation |
Inhibitors of hepatitis c virus ns3 protease
|
US7816326B2
(en)
*
|
2004-02-27 |
2010-10-19 |
Schering Corporation |
Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
|
BRPI0508095A
(pt)
*
|
2004-02-27 |
2007-07-17 |
Schering Corp |
compostos como inibidores de ns3 serina protease do vìrus da hepatite c
|
ES2346233T3
(es)
*
|
2004-02-27 |
2010-10-13 |
Schering Corporation |
Compuestos de azufre como inhibidores de serina proteasa ns3 del virus de la hepatitis c.
|
PE20060309A1
(es)
*
|
2004-05-06 |
2006-04-13 |
Schering Corp |
(1r,2s,5s)-n-[(1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil]-3-[(2s)-2[[[(1,1-dimetiletil)amino]carbonil]amino]-3,3-dimetil-1-oxobutil]-6,6-dimetil-3-azabiciclo[3.1.o]hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de l
|
CN1984922A
(zh)
*
|
2004-05-20 |
2007-06-20 |
先灵公司 |
用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的取代脯氨酸
|
US8642596B2
(en)
|
2004-12-06 |
2014-02-04 |
Siga Technologies, Inc. |
Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses
|
US7994221B2
(en)
|
2004-12-06 |
2011-08-09 |
Siga Technologies, Inc. |
Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
|
GB0426661D0
(en)
*
|
2004-12-06 |
2005-01-05 |
Isis Innovation |
Pyrrolidine compounds
|
US8410149B2
(en)
|
2004-12-06 |
2013-04-02 |
Siga Technologies Inc. |
Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
|
WO2006130666A2
(en)
*
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Medicaments and methods combining a hcv protease inhibitor and an akr competitor
|
WO2006130627A2
(en)
*
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Methods for treating hepatitis c
|
WO2006130686A2
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Hcv protease inhibitors in combination with food
|
US20060276406A1
(en)
*
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Methods of treating hepatitis C virus
|
US20060275366A1
(en)
*
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Controlled-release formulation
|
CA2611155A1
(en)
*
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Pharmaceutical formulations and methods of treatment using the same
|
US20060281689A1
(en)
*
|
2005-06-02 |
2006-12-14 |
Schering Corporation |
Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
|
WO2006130554A2
(en)
*
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Methods of treating hepatitis c virus
|
US20070021351A1
(en)
*
|
2005-06-02 |
2007-01-25 |
Schering Corporation |
Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
|
EP1898941A2
(en)
*
|
2005-06-02 |
2008-03-19 |
Schering Corporation |
Controlled-release formulation useful for treating disorders associated with hepatitis c virus
|
US7608592B2
(en)
*
|
2005-06-30 |
2009-10-27 |
Virobay, Inc. |
HCV inhibitors
|
EP2305695A3
(en)
*
|
2005-07-25 |
2011-07-27 |
Intermune, Inc. |
Macrocyclic inhibitors of Hepatitis C virus replication
|
PE20070211A1
(es)
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
SI2194043T1
(sl)
*
|
2005-08-19 |
2014-04-30 |
Vertex Pharmaceuticals Incorporated |
Postopki
|
US8399615B2
(en)
*
|
2005-08-19 |
2013-03-19 |
Vertex Pharmaceuticals Incorporated |
Processes and intermediates
|
US7964624B1
(en)
|
2005-08-26 |
2011-06-21 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
AR055395A1
(es)
|
2005-08-26 |
2007-08-22 |
Vertex Pharma |
Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
|
CN101415705B
(zh)
|
2005-10-11 |
2011-10-26 |
因特蒙公司 |
抑制丙型肝炎病毒复制的化合物和方法
|
AR056805A1
(es)
*
|
2005-11-14 |
2007-10-24 |
Schering Corp |
Un proceso para oxidacion para la preparcion de n- (3- amino-1- ( ciclobutilmetil) -2,3- dioxopropil ) -3-(n-(( ter-butilamino) carbonil )-3- metil- l- valil) -6,6- dimetil-3- azabiciclo (3.1.0) hexano -2- carboxamida y compuestos ralacionados
|
CA2634397A1
(en)
*
|
2005-12-22 |
2007-07-05 |
Schering Corporation |
Process for the preparation of 6,6-dimethyl-3-azabicyclo[3.1.0|-hexane compounds and enantiomeric salts thereof
|
WO2007078990A2
(en)
|
2005-12-23 |
2007-07-12 |
Zealand Pharma A/S |
Modified lysine-mimetic compounds
|
US7816348B2
(en)
|
2006-02-03 |
2010-10-19 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
EP1991229A2
(en)
*
|
2006-02-27 |
2008-11-19 |
Vertex Pharmaceuticals Incorporated |
Co-crystals and pharmaceutical compositions comprising the same
|
CA2646229A1
(en)
|
2006-03-16 |
2007-09-27 |
Vertex Pharmaceuticals Incorporated |
Deuterated hepatitis c protease inhibitors
|
KR101059593B1
(ko)
*
|
2006-04-11 |
2011-08-25 |
노파르티스 아게 |
Hcv/hiv 억제제 및 이들의 용도
|
WO2007120595A2
(en)
*
|
2006-04-11 |
2007-10-25 |
Novartis Ag |
Amines for the treatment of hcv
|
US7951823B2
(en)
|
2006-05-23 |
2011-05-31 |
Irm Llc |
Compounds and compositions as channel activating protease inhibitors
|
RU2008152171A
(ru)
*
|
2006-07-05 |
2010-08-10 |
Интермьюн, Инк. (Us) |
Новые ингибиторы вирусной репликации гепатита с
|
WO2008008776A2
(en)
|
2006-07-11 |
2008-01-17 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
US8329159B2
(en)
*
|
2006-08-11 |
2012-12-11 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7759495B2
(en)
*
|
2006-08-11 |
2010-07-20 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7659270B2
(en)
*
|
2006-08-11 |
2010-02-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
MX2009000882A
(es)
|
2006-08-17 |
2009-02-04 |
Boehringer Ingelheim Int |
Inhibidores de la polimerasa virica.
|
US8343477B2
(en)
|
2006-11-01 |
2013-01-01 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
US7772180B2
(en)
|
2006-11-09 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8003604B2
(en)
|
2006-11-16 |
2011-08-23 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7763584B2
(en)
|
2006-11-16 |
2010-07-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7888464B2
(en)
*
|
2006-11-16 |
2011-02-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2428204A3
(en)
*
|
2006-12-07 |
2012-07-04 |
Schering Corporation |
pH sensitive matrix formulation
|
EP2074087A2
(en)
|
2006-12-21 |
2009-07-01 |
Wyeth |
Synthesis of pyrrolidine compounds
|
WO2008074035A1
(en)
|
2006-12-27 |
2008-06-19 |
Abbott Laboratories |
Hcv protease inhibitors and uses thereof
|
EP2117537A1
(en)
*
|
2007-02-09 |
2009-11-18 |
Irm Llc |
Compounds and compositions as channel activating protease inhibitors
|
AP2009004960A0
(en)
|
2007-02-27 |
2009-08-31 |
Vertex Pharma |
Co-crystals and pharmaceutical compositions comprising the same
|
CA2679426A1
(en)
*
|
2007-02-27 |
2008-09-04 |
Luc Farmer |
Inhibitors of serine proteases
|
CA2681624A1
(en)
*
|
2007-03-23 |
2009-01-15 |
Schering Corporation |
P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease
|
US20090155209A1
(en)
*
|
2007-05-03 |
2009-06-18 |
Blatt Lawrence M |
Novel macrocyclic inhibitors of hepatitis c virus replication
|
EP2185524A1
(en)
|
2007-05-10 |
2010-05-19 |
Intermune, Inc. |
Novel peptide inhibitors of hepatitis c virus replication
|
JP2010531871A
(ja)
|
2007-07-03 |
2010-09-30 |
アクテリオン ファーマシューティカルズ リミテッド |
3−アザ−ビシクロ[3.3.0]オクタン化合物
|
NZ583487A
(en)
|
2007-07-27 |
2011-09-30 |
Actelion Pharmaceuticals Ltd |
2-aza-bicyclo[3.3.0]octane derivatives
|
EP2188274A4
(en)
|
2007-08-03 |
2011-05-25 |
Boehringer Ingelheim Int |
VIRAL POLYMERASE HEMMER
|
EP2436682A1
(en)
|
2007-08-30 |
2012-04-04 |
Vertex Pharmceuticals Incorporated |
Co-crystals and pharmaceutical compositions comprising the same
|
CN101868452B
(zh)
*
|
2007-10-10 |
2014-08-06 |
诺华股份有限公司 |
螺环吡咯烷类与其对抗hcv和hiv感染的应用
|
WO2009076747A1
(en)
|
2007-12-19 |
2009-06-25 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
WO2009085858A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Schering Corporation |
Process for the synthesis of 3-amino-3-cyclobutylmethyl-2-hydroxypropionamide or salts thereof
|
US8202996B2
(en)
|
2007-12-21 |
2012-06-19 |
Bristol-Myers Squibb Company |
Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
|
WO2009123080A1
(ja)
|
2008-04-01 |
2009-10-08 |
アステラス製薬株式会社 |
インドリノン化合物
|
MX2010011306A
(es)
*
|
2008-04-15 |
2010-11-09 |
Intermune Inc |
Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c.
|
US8163921B2
(en)
|
2008-04-16 |
2012-04-24 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
JP5529120B2
(ja)
|
2008-05-29 |
2014-06-25 |
ブリストル−マイヤーズ スクイブ カンパニー |
C型肝炎ウイルス阻害剤
|
US7964560B2
(en)
|
2008-05-29 |
2011-06-21 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
AU2009256645A1
(en)
|
2008-06-10 |
2009-12-17 |
Novartis Ag |
Pyrazine derivatives as epithelial sodium channel blockers
|
CN102131813B
(zh)
|
2008-06-24 |
2014-07-30 |
科德克希思公司 |
用于制备基本上立体异构纯的稠合二环脯氨酸化合物的生物催化方法
|
MX2011000104A
(es)
*
|
2008-07-03 |
2011-02-22 |
Vertex Pharma |
Preparacion de alfa-ceto beta-amino esteres y amidas protegidos.
|
US8188137B2
(en)
|
2008-08-15 |
2012-05-29 |
Avila Therapeutics, Inc. |
HCV protease inhibitors and uses thereof
|
US8207341B2
(en)
|
2008-09-04 |
2012-06-26 |
Bristol-Myers Squibb Company |
Process or synthesizing substituted isoquinolines
|
US8563505B2
(en)
|
2008-09-29 |
2013-10-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8044087B2
(en)
|
2008-09-29 |
2011-10-25 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8283310B2
(en)
|
2008-12-15 |
2012-10-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2010080874A1
(en)
|
2009-01-07 |
2010-07-15 |
Scynexis, Inc. |
Cyclosporine derivative for use in the treatment of hcv and hiv infection
|
AR075584A1
(es)
*
|
2009-02-27 |
2011-04-20 |
Intermune Inc |
COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
|
US20110182850A1
(en)
*
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
US20120244122A1
(en)
|
2009-05-28 |
2012-09-27 |
Masse Craig E |
Peptides for the Treatment of HCV Infections
|
WO2010138791A1
(en)
|
2009-05-29 |
2010-12-02 |
Schering Corporation |
Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
|
AR077139A1
(es)
|
2009-06-23 |
2011-08-03 |
Gilead Sciences Inc |
Composiciones farmaceuticas utiles para tratar el vch
|
AU2009352688B2
(en)
|
2009-09-15 |
2014-04-17 |
Taigen Biotechnology Co., Ltd. |
HCV protease inhibitors
|
MX2012003500A
(es)
*
|
2009-09-28 |
2012-08-01 |
Intermune Inc |
Nuevos inhibidores macrocíclicos de la replicación de virus de la hepatitis c.
|
WO2011066241A1
(en)
|
2009-11-25 |
2011-06-03 |
Schering Corporation |
Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
|
US20130156731A1
(en)
|
2009-12-22 |
2013-06-20 |
Kevin X. Chen |
Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
|
US8686145B2
(en)
|
2010-02-25 |
2014-04-01 |
Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patientenzorg C/O Technology Transfer Officer VU & Vumc |
Process for the preparation of α-acyloxy β-formamido amides
|
ES2558554T3
(es)
|
2010-03-09 |
2016-02-05 |
Merck Sharp & Dohme Corp. |
Compuestos de sililo tricíclicos condensados y métodos de uso de los mismos para el tratamiento de enfermedades víricas
|
WO2012018534A2
(en)
|
2010-07-26 |
2012-02-09 |
Schering Corporation |
Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
|
EP2621279B1
(en)
|
2010-09-29 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
|
CN102010425B
(zh)
*
|
2010-11-04 |
2013-04-10 |
山东大学 |
1,4-二硫-7-氮杂螺[4,4]壬烷-8-羧酸衍生物类组蛋白去乙酰化酶抑制剂及其应用
|
WO2012142075A1
(en)
|
2011-04-13 |
2012-10-18 |
Merck Sharp & Dohme Corp. |
2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
EA201391519A1
(ru)
|
2011-04-13 |
2014-03-31 |
Мерк Шарп И Доум Корп. |
2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний
|
US8957203B2
(en)
|
2011-05-05 |
2015-02-17 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8691757B2
(en)
|
2011-06-15 |
2014-04-08 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US20130267699A1
(en)
|
2011-06-24 |
2013-10-10 |
California Institute Of Technology |
Quaternary heteroatom containing compounds
|
US8822679B2
(en)
*
|
2011-06-24 |
2014-09-02 |
California Institute Of Technology |
Quaternary heteroatom containing compounds
|
WO2013033901A1
(en)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
|
WO2013033899A1
(en)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
|
WO2013033900A1
(en)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
|
WO2013039876A1
(en)
|
2011-09-14 |
2013-03-21 |
Merck Sharp & Dohme Corp. |
Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
|
UY34402A
(es)
|
2011-10-21 |
2013-05-31 |
Abbvie Inc |
Métodos para el tratamiento de hcv
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
CN104023726A
(zh)
|
2011-10-21 |
2014-09-03 |
艾伯维公司 |
用于治疗hcv的一种或多种daa的联合治疗(例如,与abt-072或abt-333)
|
US20130123325A1
(en)
|
2011-11-14 |
2013-05-16 |
Sven Ruf |
Use of boceprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
|
KR101996700B1
(ko)
*
|
2011-12-23 |
2019-07-04 |
입센 메뉴팩츄링 아일랜드 리미티드 |
치료 펩티드의 합성 방법
|
WO2013178682A2
(en)
|
2012-05-30 |
2013-12-05 |
Chemo Ibérica, S.A. |
Multicomponent process for the preparation of bicyclic compounds
|
WO2014053533A1
(en)
|
2012-10-05 |
2014-04-10 |
Sanofi |
Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
|
LT2909205T
(lt)
|
2012-10-19 |
2016-12-27 |
Bristol-Myers Squibb Company |
9-metilpakeistieji heksadekahidrociklopropa(e)pirolo (1,2-a)(1,4)diazaciklopentadecinilkarbamato dariniai, kaip nestruktūrinės 3 (ns3) proteazės inhibitoriai, skirti hepatito c viruso infekcijų gydymui
|
EP2914598B1
(en)
|
2012-11-02 |
2017-10-18 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
WO2014070964A1
(en)
|
2012-11-02 |
2014-05-08 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
US9643999B2
(en)
|
2012-11-02 |
2017-05-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2014070974A1
(en)
|
2012-11-05 |
2014-05-08 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
CN105164148A
(zh)
|
2013-03-07 |
2015-12-16 |
百时美施贵宝公司 |
丙型肝炎病毒抑制剂
|
EP2805705B1
(en)
|
2013-05-23 |
2016-11-09 |
IP Gesellschaft für Management mbH |
Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid
|
CN103387510B
(zh)
*
|
2013-08-08 |
2015-09-09 |
苏州永健生物医药有限公司 |
一种β-氨基-alpha-羟基环丁基丁酰胺盐酸盐的合成方法
|
US10167298B2
(en)
|
2013-10-30 |
2019-01-01 |
Merck Sharp & Dohme Corp. |
Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
|
TWI659019B
(zh)
|
2014-02-28 |
2019-05-11 |
日商帝人製藥股份有限公司 |
吡唑醯胺衍生物
|
US10421696B2
(en)
|
2014-12-18 |
2019-09-24 |
California Institute Of Technology |
Enantioselective synthesis of α-quaternary mannich adducts by palladium-catalyzed allylic alkylation
|
CA2981041C
(en)
|
2015-03-27 |
2023-09-05 |
California Institute Of Technology |
Asymmetric catalytic decarboxylative alkyl alkylation using low catalyst concentrations and a robust precatalyst
|
EP3426391A4
(en)
|
2016-03-11 |
2019-08-28 |
California Institute of Technology |
COMPOSITIONS AND METHODS FOR ACYLATING LACTAMEN
|
US11192914B2
(en)
|
2016-04-28 |
2021-12-07 |
Emory University |
Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
|
EA201990069A1
(ru)
|
2016-06-21 |
2019-06-28 |
ОРИОН ОФТАЛМОЛОДЖИ ЭлЭлСи |
Производные гетероциклического пролинамида
|
US10526315B2
(en)
|
2016-06-21 |
2020-01-07 |
Orion Ophthalmology LLC |
Carbocyclic prolinamide derivatives
|
WO2017222917A1
(en)
*
|
2016-06-21 |
2017-12-28 |
Inception 4, Inc. |
Aliphatic prolinamide derivatives
|
CN110709096B
(zh)
|
2017-05-05 |
2023-10-31 |
泽兰德制药公司 |
细胞间隙连接通讯调节剂及其在糖尿病性眼病治疗中的应用
|
US10358422B2
(en)
|
2017-11-01 |
2019-07-23 |
California Institute Of Technology |
Methods for enantioselective allylic alkylation of esters, lactones, and lactams with unactivated allylic alcohols
|
EP3699173A1
(en)
|
2018-10-18 |
2020-08-26 |
California Institute of Technology |
Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same
|
WO2021226546A1
(en)
*
|
2020-05-08 |
2021-11-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Protease inhibitors for treatment or prevention of coronavirus disease
|
US11351149B2
(en)
|
2020-09-03 |
2022-06-07 |
Pfizer Inc. |
Nitrile-containing antiviral compounds
|
WO2022208113A1
(en)
*
|
2021-04-01 |
2022-10-06 |
Heptares Therapeutics Limited |
Sars-cov-2 mpro inhibitor compounds
|
IL309732A
(en)
|
2021-07-09 |
2024-02-01 |
Aligos Therapeutics Inc |
Antiviral compounds
|
CN114149415A
(zh)
*
|
2021-07-26 |
2022-03-08 |
中国药科大学 |
一种拟肽类化合物及其衍生物、制备方法、药物组合物和应用
|
WO2023011443A1
(zh)
*
|
2021-08-02 |
2023-02-09 |
北京华益健康药物研究中心 |
用于治疗或预防冠状病毒感染的3cl蛋白酶小分子抑制剂及其用途
|
WO2023133174A1
(en)
*
|
2022-01-07 |
2023-07-13 |
Merck Sharp & Dohme Llc |
Protease inhibitors for treating or preventing coronavirus infection
|